VCM
ELVN icon

Versant Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Versant Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80.2K Buy
1,581
+6
+0.4% +$255 0.01% 1052
2026
Q1 		$61.7K Buy
1,575
+1,363
+643% +$37.8K 0.01% 1108
2025
Q4 		$3.27K Sell
212
-333
-61% -$6.63K ﹤0.01% 2364
2025
Q3 		$11.2K Buy
545
+266
+95% +$5.36K ﹤0.01% 1886
2025
Q2 		$5.6K Buy
279
+212
+316% +$4.01K ﹤0.01% 2113
2025
Q1 		$1.32K Hold
67
– – ﹤0.01% 2321
2024
Q4 		$1.51K Hold
67
– – ﹤0.01% 2113
2024
Q3 		$1.71K Buy
+67
New +$1.55K ﹤0.01% 1610

Other funds holding ELVN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $77B AUM 50.57% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
FIA
FNY Investment Advisers New York $277M AUM 98.95% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return